eikon therapeutics valuation

Our team brings decades of clinical and regulatory experience to these development programs, combined with scientific rigor born from the integration of advanced engineering, sophisticated data analysis, and breakthrough research utilizing AI-powered super-resolution microscopy, said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics. Dr. Perlmutter and the Eikon team will benefit from the expertise and insights of a distinguished, interdisciplinary Scientific Advisory Board (SAB), including: Quantifying real-time protein dynamics in cells and translating these insights into drug discovery requires a unique collaboration of world-class chemists, physicists, biologists and engineers working in concert. Super-resolution microscopy was first developed by Eric Betzig, PhD, and collaborators, who received the Nobel Prize in Chemistry in 2014 for this work. Enter your email below to receive job recommendations for similar positions. Our team has a well-documented track record of developing some of the worlds most therapeutically meaningful and commercially successful medicines. All rights reserved. Eikon Therapeutics is a drug discovery and development company working to advance breakthrough therapeutics through the purposeful integration of engineering and science. Bristol Myers Squibbs heart drug Camzyos has been recommended by the National Institute for Health and Care Excellence as the medication inches closer to approval in the UK and Europe. WebOverview Financings Valuation Enterprise Value (based on primary financings) View Enterprise Value for Eikon Therapeutics. when applying to a job online, never give your social security number to a prospective employer, provide credit card or bank account information, or perform any sort of monetary transaction. The test, approved in 2021, reaped $55 million in sales last year, but now the company is setting its sights on a new market: patients suspected of having cancer due to symptoms such as abdominal pain, rectal bleeding or unexplained weight loss. Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely. Eikon and Impact plan to file a U.S. Investigational New Drug (IND) Application for this program by the end of the third quarter of 2023. Already registered? Using an interdisciplinary approach that combines engineering and science, we have created an exciting new window into cell biology and pharmacology. A flurry of Eikon news today: - $106M Series C first tranche - At "meaningful step-up" to Series B valuation - In-licensing TLR7/8 agonists from 7/8Bio - In-licensing PARP1 inhibitors from Impact - Preclinical deal with Cleave Therapeutics The financing included strong participation from existing investors as well as adding several new strategic investors. Eikon Therapeutics Company Profile: Valuation & Investors | PitchBook Eikon Therapeutics Eikon Therapeutics Overview Update this profile Founded 2019 SHANGHAI'S MOST ACTIVE NICKEL CONTRACT RISES 3.2% TO 161,700 YUA… US Congress averts historic default, approves debt-limit suspension, Deadly protests rock Senegal as opposition leader sentenced to jail, Global shares, U.S. yields rose after strong jobs data, debt ceiling passage, Russia says US hacked thousands of Apple phones in spy plot, Dollar edges higher after larger-than-expected rise in May payrolls, US drugmaker Indivior to pay $102.5 million to settle Suboxone monopoly claims, Gold slips as yields gain after US payrolls rise, Oil up over 2% after US debt deal and jobs data; focus turns to OPEC+, Ukraine says it downed 36 Russian missiles and drones. AtomVie Global Radiopharma Inc, a Canadian radiopharmaceutical contract manufacturer, has received additional funds to get its manufacturing facility up and running. Demonstrated ability to effectively manage multiple responsibilities concurrently and quickly adjust to changing circumstances. Pictured: Golden Gate Bridge/iStock, bloodua. HAYWARD, Calif. June 16, 2022 Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance "This team is fully integrated within our organization and is working alongside our advanced engineering and research team, who have dramatically accelerated the performance of our pioneering Single Molecule Tracking (SMT) technology. Log in. Please note the magic link is 3M, the manufacturer known for making office supplies and tape, is adding to its biotech manufacturing capabilities with a $146 million investment. To unlock your profile and take advantage of all features on CareerBuilder.com, you need first to upload or build a resume, Help us improve CareerBuilder by providing feedback about this job: We'll e-mail you a link to set a new password. Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced it has acquired exclusive rights to multiple early- to mid-stage assets, leveraging its proprietary Single Molecule Tracking (SMT) technology to drive strategic All rights reserved. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. We and our third-party partners use cookies and other technologies to improve your user experience, collect browsing information, for advertising, and other purposes when you use our websites and apps. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. Eikon aims to change this with proprietary, purpose-built platforms that permit precise characterization of protein interactions in living cells with exceptional spatial and temporal resolution. Earlier in his career, Dr. Perlmutter was a Professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, Seattle, and served as Chairman of its Department of Immunology, where he was an Investigator of the Howard Hughes Medical Institute. Eikon Therapeutics Merck Ken Frazier Identify operational improvements that will benefit future project teams. when applying to a job online, never give your social security number to a prospective employer, provide credit card or bank account information, or perform any sort of monetary transaction. She has over two decades of regulatory experience in the biotechnology industry, including an extended tenure at Amgen, working on INDs/CTAs and NDAs/BLAs/MAAs across various therapeutic areas and all phases of drug development globally. Adam Goulburn, a partner at Lux Capital, was first struck by Eikon Therapeutics pitch to use super microscopes to develop drugs when founder Eric Betzig posed a simple question: How can you understand life if you dont look at it live? Please note the magic link is The pharmaceutical industry has long been limited in the tools available to study dynamic regulatory mechanisms in living cells, said Dr. Perlmutter. Eikon Therapeutics, a drug discovery and development company, has signed a lease to open a New York City operations base at the Alexandria Center for Life Science at 430 E. 29th St. After raising more than $660 million in less than a year, Eikon Therapeutics' future plans are coming into clearer view, with an oncology pipeline underway as the star-studded biotech looks to capitalize onand expandNobel Prize-winning tech. These highly sophisticated, AI-driven, protein population dynamics measurements will influence the design of clinical trials. Apply on company site. The blood testing company has long held that people are often diagnosed with cancer too late. WebInvestors 18 Funding Eikon Therapeutics has raised a total of $666M in funding over 3 rounds. By Max Bayer Jun 30, 2022 02:20pm. Copyright 2023 Surperformance. Copyright 2023 Forge Global, Inc. All rights reserved. To use our website, you must agree with the Impact CEO Sui Xiong Cai, Ph.D., said, The Eikon team brings years of experience in oncology to the development of these important assets. MarketScreener: Created by Investors for Investors! Eikon Therapeutics is a drug discovery and development company working to advance breakthrough therapeutics through the purposeful integration of engineering The partnership also includes a second brain-penetrant PARP1-selective inhibitor that Eikon will collaborate with Impact to take forward into the clinic. We are not responsible for the content or availability of linked sites. Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and Learn more. As part of its agreement with Impact Therapeutics, Eikon will work to bring the IND-ready asset IMP1734, a highly selective PARP1 inhibitor, into clinical development. Industry veteran Roger M. Perlmutter MD, PhD to join as CEO. Combining this pioneering platform with Rogers leadership and the Eikon team's drug development pedigree, puts the company at the very forefront of discovery in the biotech industry.. Our team has a well-documented track record of developing some of the worlds most therapeutically meaningful and commercially successful medicines. Unlock this article along with other benefits by subscribing to one of our paid plans. WebToday we are announcing 3 strategic licensing agreements for an array of #oncology assets, supported by new equity financing. Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily and it's free. The TikTok ad debut is timed around the ASCO medical conference, but the work is aimed more broadly at healthcare professionals, as well as people touched by cancer and people interested in advancing Black and general health equity. Eikon Therapeutics, co-founded by Betzig, is a biopharmaceutical company with plans to use super-resolution fluorescence microscopy, the data collected by these Led by biopharma titan Roger Perlmutter, Eikon Therapeutics kicked off 2022 with a Series B financing worth $517.8 Job Details. Impact CEO Sui Xiong Cai, Ph.D., said, The Eikon team brings years of experience in oncology to the development of these important assets. Each of these new programs will complement the progress we have made in our pioneering discovery platform, translating protein population dynamics measurements into discoveries that will enable the development of important new medicines.. Learn more. The company has also licensed a portfolio of PARP1-selective inhibitors invented by Impact Therapeutics and intended to improve upon existing unselective dual PARP1/2 inhibitory agents in cancer treatment. The test, approved in 2021, reaped $55 million in sales last year, but now the company is setting its sights on a new market: patients suspected of having cancer due to symptoms such as abdominal pain, rectal bleeding or unexplained weight loss. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to measure the real-time movement of individual proteins and protein populations in living cells, with the goal of bringing important new medicines to people suffering from grievous illness. Obstructive HCM is a heart condition that occurs when part of the muscular wall in the heart becomes thicker, which can then reduce blood supply to the rest of the body. The companys proprietary single-particle tracking platform enables them to peer into live cells, in real-time, and derive biological insights never visualized before, said Adam Goulburn, PhD, Partner at Lux Capital. The senior industry professionals appointed to lead the Eikon Clinical Development team include: Mei Ling Chang-Lok, Ph.D., RAC, Vice President, Regulatory Chang-Lok joined from Ventyx where she served as Vice President, Regulatory. By registering, you agree to Forges Terms of Use. She has deep industry experience in biotechnology and pharmaceutical companies including Genmab, Merck, MedImmune and Bristol Myers Squibb, leading pivotal trial registration and BTD/sBLA filings. Harry Raftopoulos, M.D., Senior Vice President, Clinical Research Oncology Raftopoulos joined from Bayer Pharmaceuticals, where he most recently served as Head of Late-Stage Oncology Clinical Development. Our business development strategy is focused on high-potential assets that Eikon is uniquely positioned to develop, and which complement our internal discovery programs, said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon. "In support of our vision to build a global biotechnology company focused on developing important new medicines, we have recruited a sophisticated team of industry experts who have decades of collective experience in managing every component of advancing new drug candidates from their earliest stages through the clinic to regulatory approval," said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics. Andrew Dunn Biopharma Correspondent Eikon Therapeutics announced three business development deals on Thursday, effectively dropping in a pipeline of Develop fit-for-purpose communication strategies for use within teams and to/from key stakeholders, including executive-level management and Eikon's Board of Directors. With the acquisition of these very different clinical assets, Eikon has taken an important step in building a diverse portfolio, at different stages of the development cycle, which address significant unmet medical needs. We are delighted the Eikon team will continue our progress in the TLR7/8 field and will conduct the future clinical development and ultimately commercialize our novel TLR7/8 agonists. All rights reserved. In final draft guidance released Friday, NICE recommended mavacamten (branded as Camzyos) as an add-on to standard care for symptomatic obstructive hypertrophic cardiomyopathy. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly. Under the collaboration agreement, Eikon received an exclusive license to co-develop, register, manufacture and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China (mainland China, Hong Kong, Macau, and Taiwan). Eikon Therapeutics is a drug discovery and development company. Illumina CEO Francis deSouza survived a threat to his board seat by securing more than twice the shareholder votes than his challenger. Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced it has acquired exclusive rights to multiple early- to mid-stage assets, leveraging its proprietary Single Molecule Tracking (SMT) technology to drive strategic decisions around its new drug pipeline. The development of these early-stage candidates is supported by Eikons pioneering applications of super-resolution microscopy, which permit protein population dynamics measurements in millions of live cells per day, in real time. Our team brings decades of clinical and regulatory experience to these development programs, combined with scientific rigor born from the integration of advanced engineering, sophisticated data analysis, and breakthrough research utilizing AI-powered super-resolution microscopy, said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and automation with the goal of bringing important new medicines to patients suffering from grievous illness. Eikon Therapeutics is a drug discovery and development company working to advance breakthrough therapeutics through the purposeful integration of engineering This approach requires the integration of tools that support advanced imaging, high-performance computing, molecular and cellular biology, medicinal chemistry, and robotics. Under the collaboration agreement, Eikon received an exclusive license to co-develop, register, manufacture and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China (mainland China, Hong Kong, Macau, and Taiwan). HAYWARD, Calif., June 01, 2023--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a clinical stage biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced its Clinical Development organization. Bristol Myers Squibbs heart drug Camzyos has been recommended by the National Institute for Health and Care Excellence as the medication inches closer to approval in the UK and Europe. This positions Eikon well to bring a broad range of new drug candidates successfully through regulatory review and approval to people who seek better treatments for a range of grievous illnesses.. Notably, Dr. Perlmutter helped Merck establish KEYTRUDA as a foundational immunotherapy for cancer care. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. Under his R&D leadership, Merck received more than 100 regulatory approvals for its medicines and vaccines globally, including those for multiple cancers, diabetes, and infectious diseases. View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005390/en/. Gilead Sciences is taking over the opening page on TikTok for the next two weeks. HAYWARD, Calif.--(BUSINESS WIRE)-- Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the Biotech company Eikon Therapeutics to open New York City operations base, Fierce Next Gen: Eikon drops hints at early pipeline, plans for $660M-plus reservoir, How can you understand life if you dont look at it live? Eikon Therapeutics rakes in $518M. Eikon is based in Hayward, California and can be found online via our website or on Twitter or LinkedIn. Bachelor's degree required; in a life sciences field is preferred. Tammie Denyse speaks up about Black women and breast cancer inequity in Gilead's first TikTok campaign. Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily and it's free. for use of our website. SHANGHAI and HAYWARD, Calif., June 1, 2023 /PRNewswire/ -- IMPACT Therapeutics ("Impact"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, and Eikon Therapeutics ("Eikon"), a biotechnology company that is advancing breakthrough To unlock your profile and take advantage of all features on CareerBuilder.com, you need first to upload or build a resume, Help us improve CareerBuilder by providing feedback about this job: GSK launched a new initiative on Thursday and committed up to $1 million in grant funding to improve adult routine vaccination rates. If seemingly healthy people were screened for early signs of the disease before symptoms appear, they may be able to get more effective treatments that nip cancer in the bud. The partnership also includes a second brain-penetrant PARP1-selective inhibitor that Eikon will collaborate with Impact to take forward into the clinic. PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. A flurry of Eikon news today: - $106M Series C first tranche - At "meaningful step-up" to Series B valuation - In-licensing TLR7/8 agonists from 7/8Bio - In-licensing GLP/GMP experience is a plus. and both meet and comply with their provisions. when applying to a job online, never give your social security number to a prospective employer, provide credit card or bank account information, or perform any sort of monetary transaction. This first Series C close brings Eikons total capital raised to nearly $775 million since its founding in late 2019. The blood testing company has long held that people are often diagnosed with cancer too late. eikontx.comHealthcareFounded: 2019Funding to Date: $1.21B. Grails vision is simple but bold. The development of these early-stage candidates is supported by Eikons pioneering applications of super-resolution microscopy, which permit protein population dynamics measurements in millions of live cells per day, in real time. Together, they position Eikon to become a fully integrated global biotechnology company. We and our third-party partners use cookies and other technologies to improve your user experience, collect browsing information, for advertising, and other purposes when you use our websites and apps. The Hayward, CA-based company has become one of biotechs richest startups since its 2019 founding, having raised nearly $775 million. This site requires JavaScript to work correctly. The DNA sequencing company also appointed Scott Ullem, the CFO of Edwards Lifesciences, to the board, according to a company statement. I feel privileged to have the opportunity to work with Drs. Prior to joining Eikon, Dr. Perlmutter was an executive vice president at Merck and president of Merck Research Laboratories. At the heart of our industry is a focus on developing and delivering medicines for some of the worlds most challenging diseases, including those that have few or no effective treatments today. WebHAYWARD, Calif. January 6, 2022 Eikon Therapeutics, Inc., a pioneer in the application of live-cell super-resolution microscopy to drug discovery, today announced A Gilead-sponsored video, featuring cancer advocates talking about equity and other issues, will show up as the landing page, called the For You page, for millions of TikTok watchers. Its developing a massive, automated research approach built around Nobel Prize-winning microscope science to peer inside cells and watch proteins in action. By applying to a job using CareerBuilder you are agreeing to comply with and be subject to the CareerBuilder GSK launched a new initiative on Thursday and committed up to $1 million in grant funding to improve adult routine vaccination rates. Prior to that he had a clinical leadership role on the Keytruda program at Merck and was responsible for key pivotal studies in non-small cell lung cancer. Eikon Therapeutics is a drug discovery and development company working to advance breakthrough therapeutics through the purposeful integration of engineering In-depth understanding of the drug discovery process, including target identification, library screening, lead optimization, preclinical testing. Image courtesy of The Janssen Pharmaceutical Companies of Johnson & Johnson. Weve seen a remarkable pace of transformational innovation, applied research, and advanced clinical development over the last decade. Eikon Therapeutics was founded in 2019 by Luke Lavis, Robert Tjian Ph.D., Xavier Darzacq Ph.D., and Eric Betzig and is headquartered in Hayward, CA. Weve seen a remarkable pace of transformational innovation, applied research, and advanced clinical development over the last decade. In this context, it is inspiring to see what Eikon has already accomplished by incorporating physics and engineering along with machine learning to complement traditional drug discovery approaches. Web2,077 Highlights Total Funding Amount $666M Contacts 50 Employee Profiles 4 Investors 18 Similar Companies 288 Find More Contacts for Eikon Therapeutics Ashish Kheterpal Our proprietary platform leverages super-resolution microscopy, a Nobel Prize-winning technology, as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of developing and bringing to market novel therapies. Copyright 2023 Surperformance. After its Series B last year, PitchBook reported a $3.02 billion valuation. All rights reserved. For more details on financing and valuation for Eikon Therapeutics, register or login. $665.8M Investors Count 18 Funding, Valuation & Revenue 3 Fundings Eikon Therapeutics's latest funding round was a Series B for $517.8M on January 6, Illuminas board appointed two new members, including Hologic CEO Stephen MacMillan as the non-executive chair, a move that followed a proxy fight that saw shareholders oust the companys board chair. President, Chief Executive Officer & Chairman, Chief Medical Officer & Executive Vice President. Yet much of the scientific communitys understanding of these biological systems is based on static snapshots, typically obtained using frozen or fixed material. These highly sophisticated, AI-driven, protein population dynamics measurements will influence the design of clinical trials. Facilitate regular team meetings, ensuring alignment on objectives and progress. WebEikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to Report this job. WebAbout Eikon Therapeutics Stock. https://bwnews.pr/43fHcBq #media, #asco23, #businessdevelopment #cancerresearch #cancertreatment View source version on businesswire.com: https://www.businesswire.com/news/home/20230601005469/en/, Media Inquiries:Lisa McCormick [email protected], https://www.businesswire.com/news/home/20230601005469/en/, US STOCKS-Wall Street rallies after jobs data; debt default averted, YouTube to stop removing content making false claims on past elections, UPDATE 1-US natgas up 1% on forecast for more demand, record exports to Mexico, UPDATE 1-Tyson Foods to cut 262 employees in South Dakota who opt not to relocate, UPDATE 1-Outsized US job gains may mask signs of weakness.